Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Exclusion Criteria

• •Use of systemic chronic steroid therapy (≥10mg /day of prednisone or equivalent), or any immunosuppressive therapy within 7 days of first dose of study treatment. Topical, inhaled, nasal, or ophthalmic steroids are allowed.
• •Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type.
• •Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur.
• •Patients with prior known toxicity attributed to PD-1 or PDL-1 directed therapy, which led to discontinuation of these agents, will be excluded from the PDR001 containing arms of the study.
• •Patients with prior known toxicity from IL-17A directed therapy, which led to discontinuation of the study treatment, will be excluded from CJM112 containing arms of the study.
• •Any of the following clinical laboratory results during screening (i.e., within 28 days before the first dose of study treatment):
• •* Absolute neutrophil count (ANC) \< 1,000/mm3 without growth factor support within 7 days prior to testing
• •* Platelet count \< 75,000 mm3 without transfusion support within 7 days prior to testing
• •* Bilirubin \> 1.5 times the upper limit of the normal range (ULN)
• •* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 times the ULN